Results 1 to 10 of about 650,104 (308)

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +2 more sources

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

PLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao, Yanfeng Qi, Yan Yang, Xichun Liu, Duo Xu, Wei Guo, Yang Zhan, Zhenggang Xiong, Allen Zhang, Alun R Wang, Xueqi Fu, Haitao Zhang, Lijing Zhao, Jingkai Gu, Yan Dong   +14 more
doaj   +2 more sources

Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer

Pharmaceutics, 2021
Heat shock protein 27 (Hsp27) has an established role in tumor progression and chemo-resistance of castration-resistant prostate cancer (CRPC). Hsp27 protects eukaryotic translation initiation factor 4E (eIF4E) from degradation, thereby maintaining ...
Hajer Ziouziou, Clément Paris, Sébastien Benizri, Thi Khanh Le, Claudia Andrieu, Dang Tan Nguyen, Ananda Appavoo, David Taïeb, Frédéric Brunel, Ridha Oueslati, Olivier Siri, Michel Camplo, Philippe Barthélémy, Palma Rocchi   +13 more
doaj   +1 more source

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1

Communications Biology, 2022
Through comparative genomics using PDX models of androgen-dependent (AD) and androgen-resistant (AR) tumors, Makino et al. identify opioid receptor kappa 1 (OPRK1) as being associated with castration-resistance.
Yuki Makino, Yuki Kamiyama, J. B. Brown, Toshiya Tanaka, Ryusuke Murakami, Yuki Teramoto, Takayuki Goto, Shusuke Akamatsu, Naoki Terada, Takahiro Inoue, Tatsuhiko Kodama, Osamu Ogawa, Takashi Kobayashi   +12 more
doaj   +1 more source

RGS2 is prognostic for development of castration resistance and cancer‐specific survival in castration‐resistant prostate cancer [PDF]

The Prostate, 2020
AbstractBackgroundRegulator of G‐protein signaling 2 (RGS2) is a multifaceted protein with a prognostic value in hormone‐naïve prostate cancer (PC). It has previously been associated with the development of castration resistance. However, RGS2 expression in clinical specimens of castration‐resistant prostate cancer (CRPC) and its clinical relevance has
Anna Linder, Karin Larsson, Karin Welén, Jan‐Erik Damber   +3 more
openaire   +2 more sources

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

Nonmetastatic Castration-Resistant Prostate Cancer [PDF]

Korean Journal of Urology, 2014
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation.
Hong, Jun Hyuk, Kim, Isaac Y.
openaire   +2 more sources

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Frontiers in Oncology, 2023
Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant.
Diana V. Maslov, Quinne Sember, Jason Cham, Munveer Bhangoo   +3 more
doaj   +1 more source